The Week in Biopharma, Feb. 7-13
Contract Research Organizations (CRO)
- KCAS Acquires FlowMetric (USA)
Contract Development and Manufacturing Organization (CDMO)
- Berkshire Sterile Adds Formulation, Lyophilization, Method Development Services (USA)
- Pharma Nobis Acquires Fagron’s Contract Manufacturing Business (USA)
- DuPont Invests in Bioprocessing Supply Chain (Holland)
- Piramal Pharma Solutions Expands & Upgrades UK Facilities (UK)
- Sartorius Completes Acquisition of Novasep’s Chromatography Biz (Germany)
- CDMO Piramal earmarks $74M for upgrades to UK antibody, API manufacturing sites (UK)
- Merck KGaA forms new life sciences unit in push to strengthen its CDMO position (USA)
- Skyepharma inks deal to build largest microbiome facility in France (France)
- AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing (Germany)
- Humanigen and Cenexi Collaborate to Manufacture Lenzilumab in France (France)
- Olon Expands High Containment API Operations (Italy)
- AskBio, Touchlight Restructure Former JV, Touchlight AAV (UK)
Artificial Intelligence (AI)
- Merck KGaA, Quris Partner on BioAI Platform for Clinical Safety Prediction (USA)
- San Diego’s 1859 comes out of stealth mode with $40 million to streamline drug discovery (USA)
- X-Chem and Excelra’s GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets (UK)
- Cyclic Spins out Startup, Perturba Therapeutics, from University of Toronto (Canada)
- Gandeeva Therapeutics led by UBC professor raises US$40m to advance drug discovery (Canada)
- Elix launches kMoL: a machine learning library for AI drug discovery with federated learning (Japan)
- Pfizer extends cooperation deal with Israeli AI drug development firm CytoReason (Israel)
Biopharma
- Aptar Mumbai Celebrates Anniversary and Announces New Facility (India)
- APNAR Pharma Acquires Aurex Laboratories (India)
- Ventus Therapeutics raises funding to expedite drug discovery platform (Canada)
- Intellia expands gene editing toolkit with $45m Rewrite buy (USA)
- Mica Biosystems catapults remote stem cell therapy to trials (UK)
- Regenxbio expands MPS I gene therapy trial after first look at data (USA)
- GPB Scientific becomes Curate Biosciences, targets 50% reduction in autologous cell therapy costs. (USA)
